Elan forecasts rare profit for 2010

Increased demand for its multiple sclerosis drug Tysabri and a tie-up with Johnson & Johnson helped trim losses at Elan, leading the Irish pharma to predict that in 2010, it would make an operating profit for the first time in nine years. Report

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.